ABVX ABIVAX Société Anonyme | $9.12
-4.0% | 7/29/2024 | Initiated by | Laidlaw | - | Buy | $48.00 | Low | View details for Laidlaw rating of ABIVAX Société Anonyme (NASDAQ:ABVX) on 7/29/2024 |
MEIP MEI Pharma | $2.88
-1.4% | 7/23/2024 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of MEI Pharma (NASDAQ:MEIP) on 7/23/2024 |
AFMD Affimed | $3.16
-9.2% | 6/13/2024 | Target Raised by | Laidlaw | - | Buy | $15.00 -> $25.00 | Low | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 6/13/2024 |
PHGE BiomX | $0.58
-6.5% | 5/28/2024 | Initiated by | Laidlaw | - | Buy | $25.00 | N/A | View details for Laidlaw rating of BiomX (NYSEMKT:PHGE) on 5/28/2024 |
INAB IN8bio | $0.33
| 3/18/2024 | Initiated by | Laidlaw | - | Buy | $7.50 | Low | View details for Laidlaw rating of IN8bio (NASDAQ:INAB) on 3/18/2024 |
CING Cingulate | $4.02
-4.3% | 12/22/2023 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 12/22/2023 |
|
NLSP NLS Pharmaceutics | $3.26
+4.2% | 9/6/2022 | Initiated by | Laidlaw | - | Buy | $6.00 | Low | View details for Laidlaw rating of NLS Pharmaceutics (NASDAQ:NLSP) on 9/6/2022 |
CING Cingulate | $4.02
-4.3% | 1/20/2022 | Initiated by | Laidlaw | - | Buy | $170.00 | High | View details for Laidlaw rating of Cingulate (NASDAQ:CING) on 1/20/2022 |
AFMD Affimed | $3.16
-9.2% | 8/9/2020 | Reiterated by | Laidlaw | - | Market Perform -> Buy | $100.00 | Medium | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 8/9/2020 |
CRIS Curis | $3.80
-3.8% | 7/29/2020 | Initiated by | Laidlaw | - | Buy | $100.00 | Medium | View details for Laidlaw rating of Curis (NASDAQ:CRIS) on 7/29/2020 |
SLNO Soleno Therapeutics | $51.64
-0.3% | 6/5/2020 | Reiterated by | Laidlaw | Analyst Yale Jen | Buy | $150.00 | Low | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 6/5/2020 |
DCTH Delcath Systems | $9.74
+3.7% | 6/1/2020 | Initiated by | Laidlaw | - | Buy | $19.00 | High | View details for Laidlaw rating of Delcath Systems (NASDAQ:DCTH) on 6/1/2020 |
ALDX Aldeyra Therapeutics | $4.70
+11.6% | 5/26/2020 | Reiterated by | Laidlaw | - | Buy | $30.00 | Low | View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 5/26/2020 |
SLNO Soleno Therapeutics | $51.64
-0.3% | 12/23/2019 | Initiated by | Laidlaw | Analyst Francois Brisebois | Buy | | High | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 12/23/2019 |
EYPT EyePoint Pharmaceuticals | $8.58
-6.4% | 11/4/2019 | Initiated by | Laidlaw | - | Buy | $500.00 | High | View details for Laidlaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 11/4/2019 |
AVDL Avadel Pharmaceuticals | $10.72
-1.8% | 9/24/2019 | Target Raised by | Laidlaw | Analyst Francois Brisebois | Buy | $3.00 -> $6.00 | Low | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 9/24/2019 |
TLSA Tiziana Life Sciences | $1.03
+15.7% | 9/10/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $20.00 | N/A | View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 9/10/2019 |
EBS Emergent BioSolutions | $8.60
+11.4% | 9/4/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $72.00 | Low | View details for Laidlaw rating of Emergent BioSolutions (NYSE:EBS) on 9/4/2019 |
CLSD Clearside Biomedical | $1.02
+3.0% | 8/13/2019 | Downgraded by | Laidlaw | - | Buy -> Hold | | Low | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 8/13/2019 |
AVDL Avadel Pharmaceuticals | $10.72
-1.8% | 8/12/2019 | Upgraded by | Laidlaw | Analyst Francois Brisebois | Hold -> Buy | $3.00 | Low | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 8/12/2019 |
SLNO Soleno Therapeutics | $51.64
-0.3% | 7/8/2019 | Initiated by | Laidlaw | - | Buy | $150.00 | High | View details for Laidlaw rating of Soleno Therapeutics (NASDAQ:SLNO) on 7/8/2019 |
AFMD Affimed | $3.16
-9.2% | 7/3/2019 | Target Set by | Laidlaw | Analyst Yale Jen | Buy | $100.00 | Low | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 7/3/2019 |
CARA Cara Therapeutics | $0.29
-6.4% | 5/29/2019 | Target Raised by | Laidlaw | Analyst James Molloy | Buy | $26.00 -> $32.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 5/29/2019 |
AVDL Avadel Pharmaceuticals | $10.72
-1.8% | 3/18/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Hold | $2.00 | Medium | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 3/18/2019 |
BSGM BioSig Technologies | $1.91
+4.9% | 2/20/2019 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $110.00 | Medium | View details for Laidlaw rating of BioSig Technologies (NASDAQ:BSGM) on 2/20/2019 |
ARCT Arcturus Therapeutics | $16.27
+1.6% | 2/19/2019 | Initiated by | Laidlaw | - | Buy | | Low | View details for Laidlaw rating of Arcturus Therapeutics (NASDAQ:ARCT) on 2/19/2019 |
CARA Cara Therapeutics | $0.29
-6.4% | 12/20/2018 | Target Set by | Laidlaw | Analyst James Molloy | Buy | $30.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 12/20/2018 |
TLSA Tiziana Life Sciences | $1.03
+15.7% | 12/17/2018 | Initiated by | Laidlaw | - | Buy -> Buy | | High | View details for Laidlaw rating of Tiziana Life Sciences (NASDAQ:TLSA) on 12/17/2018 |
CLSD Clearside Biomedical | $1.02
+3.0% | 11/6/2018 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $5.00 | Low | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 11/6/2018 |
AVDL Avadel Pharmaceuticals | $10.72
-1.8% | 11/6/2018 | Downgraded by | Laidlaw | - | Buy -> Hold | $6.00 | High | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 11/6/2018 |
CLSD Clearside Biomedical | $1.02
+3.0% | 7/16/2018 | Initiated by | Laidlaw | - | Buy | $18.00 | High | View details for Laidlaw rating of Clearside Biomedical (NASDAQ:CLSD) on 7/16/2018 |
VKTX Viking Therapeutics | $49.11
-0.9% | 6/1/2018 | Target Raised by | Laidlaw | - | Buy | $10.00 -> $15.00 | High | View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 6/1/2018 |
CARA Cara Therapeutics | $0.29
-6.4% | 5/24/2018 | Target Set by | Laidlaw | Analyst Francois Brisebois | Buy | $26.00 | Low | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 5/24/2018 |
MEIP MEI Pharma | $2.88
-1.4% | 4/12/2018 | Initiated by | Laidlaw | - | Buy | $140.00 | High | View details for Laidlaw rating of MEI Pharma (NASDAQ:MEIP) on 4/12/2018 |
MRNS Marinus Pharmaceuticals | $0.31
+3.4% | 12/14/2017 | Initiated by | Laidlaw | - | Buy -> Buy | $72.00 | High | View details for Laidlaw rating of Marinus Pharmaceuticals (NASDAQ:MRNS) on 12/14/2017 |
FRX Fennec Pharmaceuticals | C$5.68
+0.5% | 11/29/2017 | Initiated by | Laidlaw | - | Buy | C$22.00 | N/A | View details for Laidlaw rating of Fennec Pharmaceuticals (TSE:FRX) on 11/29/2017 |
FENC Fennec Pharmaceuticals | $4.04
+1.0% | 11/29/2017 | Initiated by | Laidlaw | - | Buy -> Buy | $22.00 | High | View details for Laidlaw rating of Fennec Pharmaceuticals (NASDAQ:FENC) on 11/29/2017 |
EYPT EyePoint Pharmaceuticals | $8.58
-6.4% | 11/8/2017 | Initiated by | Laidlaw | - | Buy | $500.00 | N/A | View details for Laidlaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 11/8/2017 |
DRRX DURECT | $0.92
-8.9% | 10/20/2017 | Target Lowered by | Laidlaw | - | Buy -> Buy | $30.00 -> $20.00 | N/A | View details for Laidlaw rating of DURECT (NASDAQ:DRRX) on 10/20/2017 |
IONS Ionis Pharmaceuticals | $33.73
-1.8% | 8/14/2017 | Reiterated by | Laidlaw | - | Buy | $65.00 | Low | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/14/2017 |
Trump’s EPIC Stock Market Rally (Ad) Putting HUGE gain chances in the hands of hardworking, patriotic Americans like YOU.
In fact, according to Jim, getting in now could turn $10,000 into as much as $265,000 by Inauguration Day. Play this epic Trump rally for every dollar of profit possible. |
ICAD iCAD | $1.52
-7.3% | 7/25/2017 | Reiterated by | Laidlaw | - | Buy | $11.00 | Medium | View details for Laidlaw rating of iCAD (NASDAQ:ICAD) on 7/25/2017 |
CARA Cara Therapeutics | $0.29
-6.4% | 6/30/2017 | Target Lowered by | Laidlaw | - | Buy | $35.00 -> $30.00 | High | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 6/30/2017 |
AST Asterias Biotherapeutics | $0.94
-1.1% | 4/4/2017 | Initiated by | Laidlaw | - | Buy -> Buy | $12.00 | Medium | View details for Laidlaw rating of Asterias Biotherapeutics (NYSEAMERICAN:AST) on 4/4/2017 |
CARA Cara Therapeutics | $0.29
-6.4% | 3/28/2017 | Reiterated by | Laidlaw | - | Buy -> Buy | $20.00 -> $35.00 | High | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 3/28/2017 |
CARA Cara Therapeutics | $0.29
-6.4% | 3/10/2017 | Target Raised by | Laidlaw | - | Buy -> Buy | $17.00 -> $20.00 | Medium | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 3/10/2017 |
OPK OPKO Health | $1.64
| 1/3/2017 | Reiterated by | Laidlaw | - | Buy | $22.00 -> $19.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 1/3/2017 |
IONS Ionis Pharmaceuticals | $33.73
-1.8% | 12/27/2016 | Target Raised by | Laidlaw | - | Buy | $59.00 -> $65.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/27/2016 |
AXON Axon Enterprise | $600.00
+0.1% | 12/20/2016 | Initiated by | Laidlaw | - | Sell | $7.50 | N/A | View details for Laidlaw rating of Axon Enterprise (NASDAQ:AXON) on 12/20/2016 |
VKTX Viking Therapeutics | $49.11
-0.9% | 8/11/2016 | Target Lowered by | Laidlaw | - | Buy | $20.00 -> $10.00 | N/A | View details for Laidlaw rating of Viking Therapeutics (NASDAQ:VKTX) on 8/11/2016 |
CARA Cara Therapeutics | $0.29
-6.4% | 2/29/2016 | Target Lowered by | Laidlaw | - | Buy | $30.00 -> $17.00 | N/A | View details for Laidlaw rating of Cara Therapeutics (NASDAQ:CARA) on 2/29/2016 |
AVDL Avadel Pharmaceuticals | $10.72
-1.8% | 1/21/2016 | Target Lowered by | Laidlaw | - | Buy | $30.00 -> $25.00 | N/A | View details for Laidlaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 1/21/2016 |
AFMD Affimed | $3.16
-9.2% | 12/10/2015 | Initiated by | Laidlaw | - | Buy | $150.00 | N/A | View details for Laidlaw rating of Affimed (NASDAQ:AFMD) on 12/10/2015 |
OPK OPKO Health | $1.64
| 8/13/2015 | Initiated by | Laidlaw | - | Buy | $22.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/13/2015 |
OPK OPKO Health | $1.64
| 8/12/2015 | Initiated by | Laidlaw | - | Buy | $22.00 | N/A | View details for Laidlaw rating of OPKO Health (NASDAQ:OPK) on 8/12/2015 |
ALDX Aldeyra Therapeutics | $4.70
+11.6% | 1/26/2015 | Initiated by | Laidlaw | Analyst Yale Jen | Buy | $30.00 | N/A | View details for Laidlaw rating of Aldeyra Therapeutics (NASDAQ:ALDX) on 1/26/2015 |
IONS Ionis Pharmaceuticals | $33.73
-1.8% | 12/9/2014 | Target Raised by | Laidlaw | - | | $65.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 12/9/2014 |
IONS Ionis Pharmaceuticals | $33.73
-1.8% | 11/25/2014 | Reiterated by | Laidlaw | - | Buy | | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 11/25/2014 |
IONS Ionis Pharmaceuticals | $33.73
-1.8% | 8/12/2014 | Initiated by | Laidlaw | - | Buy | $52.00 | N/A | View details for Laidlaw rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 8/12/2014 |
IOVA Iovance Biotherapeutics | $8.43
+3.1% | 6/30/2014 | Initiated by | Laidlaw | - | Buy | | N/A | View details for Laidlaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 6/30/2014 |
SSYS Stratasys | $9.13
-1.4% | 3/7/2014 | Initiated by | Laidlaw | - | Buy | $145.00 | N/A | View details for Laidlaw rating of Stratasys (NASDAQ:SSYS) on 3/7/2014 |
OMCL Omnicell | $46.05
+0.8% | 3/5/2014 | Target Raised by | Laidlaw | - | Buy | $29.00 -> $34.00 | N/A | View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 3/5/2014 |
SRDX Surmodics | $39.25
+1.4% | 2/25/2014 | Initiated by | Laidlaw | - | Buy | $30.00 | N/A | View details for Laidlaw rating of Surmodics (NASDAQ:SRDX) on 2/25/2014 |
OMCL Omnicell | $46.05
+0.8% | 1/28/2014 | Target Raised by | Laidlaw | - | Buy | $27.00 -> $29.00 | N/A | View details for Laidlaw rating of Omnicell (NASDAQ:OMCL) on 1/28/2014 |
